Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Prospects for antidepressant drug discovery
Autore:
Holsboer, F;
Indirizzi:
Max Planck Inst Psychiat, D-80804 Munich, Germany Max Planck Inst Psychiat Munich Germany D-80804 D-80804 Munich, Germany
Titolo Testata:
BIOLOGICAL PSYCHOLOGY
fascicolo: 1-3, volume: 57, anno: 2001,
pagine: 47 - 65
SICI:
0301-0511(200107/08)57:1-3<47:PFADD>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORTICOTROPIN-RELEASING HORMONE-RECEPTOR-1; IMPAIRED STRESS-RESPONSE; DEXAMETHASONE-CRH TEST; HORMONE RECEPTOR-2; PARAVENTRICULAR NUCLEUS; PSYCHIATRIC-DISORDERS; EXPRESSING NEURONS; DEPRESSED-PATIENTS; CORTISOL RESPONSE; MICE LACKING;
Keywords:
depression; pharmacology; neuropeptides; neurotransmitter; receptors;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Citazioni:
45
Recensione:
Indirizzi per estratti:
Indirizzo: Holsboer, F Max Planck Inst Psychiat, Kraepelinstr 2-10, D-80804 Munich, Germany Max Planck Inst Psychiat Kraepelinstr 2-10 Munich Germany D-80804
Citazione:
F. Holsboer, "Prospects for antidepressant drug discovery", BIOL PSYCH, 57(1-3), 2001, pp. 47-65

Abstract

Recent socioeconomic analyses found that depression is a leading cause of disability and a major risk factor for development of other diseases. Moreover, on a world-wide scale depression is underdiagnosed and undertreated. Current antidepressant drugs have proven to be effective, but are burdened with slow onset of action and side effects. Above this, it is still unclear by which pharmacological mode of action they exert their clinical effects. Hypothesis-driven research based upon the corticosteroid receptor hypothesis of depression has led to a novel concept focusing on brain neuropeptide receptors, specifically the corticotropin-releasing hormone (CRH) receptor as drug target. This treatise expands on this new development, its background and its promises including first clinical experiments. In the era of functional genomics, however, hypothesis-driven research will be complemented by a new strategy that relies on a 'bottom up' search for new drug targets through screening techniques that range from the use of DNA microarrays, searches of compound libraries to behavioral screens of mouse mutants, just toname a few. In this sense, biotechnology opens up new chances for drug development through serendipity by providing new data bases on which systematic biological research in psychiatry and psychology can be conducted. (C) 2001 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 02:41:54